These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 27806638

  • 1. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.
    Molander P, Färkkilä M, Kemppainen H, Blomster T, Jussila A, Mustonen H, Sipponen T.
    Scand J Gastroenterol; 2017 Mar; 52(3):284-290. PubMed ID: 27806638
    [Abstract] [Full Text] [Related]

  • 2. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
    Molander P, Färkkilä M, Ristimäki A, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho KL, Mustonen H, Sipponen T.
    J Crohns Colitis; 2015 Jan; 9(1):33-40. PubMed ID: 25052347
    [Abstract] [Full Text] [Related]

  • 3. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
    Molander P, Färkkilä M, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho KL, Mustonen H, Sipponen T.
    Inflamm Bowel Dis; 2014 Jun; 20(6):1021-8. PubMed ID: 24798636
    [Abstract] [Full Text] [Related]

  • 4. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Romanko I, Bina V, Malickova K, Kolar M, Lukas M.
    Scand J Gastroenterol; 2016 Jun; 51(2):196-202. PubMed ID: 26329773
    [Abstract] [Full Text] [Related]

  • 5. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Muñoz C, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, Gisbert JP.
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [Abstract] [Full Text] [Related]

  • 6. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho KL, Färkkilä M.
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [Abstract] [Full Text] [Related]

  • 7. Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up.
    Lehtola E, Haapamäki J, Färkkilä MA.
    Scand J Gastroenterol; 2016 Dec; 51(12):1476-1481. PubMed ID: 27686143
    [Abstract] [Full Text] [Related]

  • 8. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
    Lee JM, Kim YJ, Lee KM, Yoon H, Lee BI, Kim DB, Kang D.
    Scand J Gastroenterol; 2018 Dec; 53(10-11):1280-1285. PubMed ID: 30351977
    [Abstract] [Full Text] [Related]

  • 9. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Gisbert JP, Marín AC, Chaparro M.
    Am J Gastroenterol; 2016 May; 111(5):632-47. PubMed ID: 27002797
    [Abstract] [Full Text] [Related]

  • 10. Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumor necrosis factor alpha therapy.
    Hlavaty T, Krajcovicova A, Letkovsky J, Sturdik I, Koller T, Toth J, Huorka M.
    Bratisl Lek Listy; 2016 May; 117(4):205-11. PubMed ID: 27075383
    [Abstract] [Full Text] [Related]

  • 11. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
    Mahmoud R, Savelkoul EHJ, Mares W, Goetgebuer R, Witteman BJM, de Koning DB, van Tuyl SAC, Minderhoud I, Lutgens MWMD, Akol-Simsek D, van Schaik FDM, Fidder HH, Jansen JM, van Boeckel PGA, Mahmmod N, Horjus-Talabur Horje CS, Römkens TEH, Colombel JF, Hoentjen F, Jharap B, Oldenburg B, Dutch Initiative on Crohn’s and Colitis (ICC) and the AWARE study group.
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):750-760.e4. PubMed ID: 36055567
    [Abstract] [Full Text] [Related]

  • 12. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F, Portela F.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228
    [Abstract] [Full Text] [Related]

  • 13. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
    Bacsur P, Skribanek S, Milassin Á, Farkas K, Bor R, Fábián A, Rutka M, Bálint A, Szántó KJ, Tóth T, Nagy F, Szepes Z, Boda K, Molnár T.
    Orv Hetil; 2020 Nov 22; 161(47):1989-1994. PubMed ID: 33226355
    [Abstract] [Full Text] [Related]

  • 14. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
    Baki E, Zwickel P, Zawierucha A, Ehehalt R, Gotthardt D, Stremmel W, Gauss A.
    World J Gastroenterol; 2015 Mar 21; 21(11):3282-90. PubMed ID: 25805935
    [Abstract] [Full Text] [Related]

  • 15. Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study.
    Song JH, Kang EA, Park SK, Hong SN, Kim YS, Bang KB, Kim KO, Lee HS, Kang SB, Shin SY, Song EM, Im JP, Choi CH, IBD Research Group of the Korean Association for the Study of Intestinal Diseases.
    Gut Liver; 2021 Sep 15; 15(5):752-762. PubMed ID: 33767028
    [Abstract] [Full Text] [Related]

  • 16. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.
    Molander P, af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho KL, Färkkilä M, Sipponen T.
    Inflamm Bowel Dis; 2012 Nov 15; 18(11):2011-7. PubMed ID: 22223566
    [Abstract] [Full Text] [Related]

  • 17. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.
    Ben-Horin S, Chowers Y, Ungar B, Kopylov U, Loebstein R, Weiss B, Eliakim R, Del Tedesco E, Paul S, Roblin X.
    Aliment Pharmacol Ther; 2015 Aug 15; 42(3):356-64. PubMed ID: 26032402
    [Abstract] [Full Text] [Related]

  • 18. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F, Polymeros D, Panagiotou M, Theodoropoulos K, Rigopoulos D.
    Acta Dermatovenerol Croat; 2016 Apr 15; 24(1):83-5. PubMed ID: 27149138
    [Abstract] [Full Text] [Related]

  • 19. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
    Nuij V, Fuhler GM, Edel AJ, Ouwendijk RJ, Rijk MC, Beukers R, Quispel R, van Tilburg AJ, Tang TJ, Smalbraak H, Bruin KF, Lindenburg F, Peyrin-Biroulet L, van der Woude CJ, Dutch Delta IBD Group.
    J Crohns Colitis; 2015 Nov 15; 9(11):997-1003. PubMed ID: 26223842
    [Abstract] [Full Text] [Related]

  • 20. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.
    Kolho KL, Sipponen T.
    Scand J Gastroenterol; 2014 Apr 15; 49(4):434-41. PubMed ID: 24597837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.